List of pharmaceutical compound number prefixes explained

This list of pharmaceutical compound number prefixes provides codes used by individual pharmaceutical companies when naming their pharmaceutical drug candidates. Pharmaceutical companies generally produce large numbers of compounds in the research phase for which it is impractical to use often long and cumbersome systematic chemical names, and for which the effort to generate nonproprietary names may not be warranted, see article on drug nomenclature. Instead, these compounds are usually given a number for internal reference at the company. To distinguish the numbered compounds from different companies (or academic laboratories), each compound number is prefixed with a letter code indicating the company that developed the compound, that claims intellectual property on that compound etc. The letter code is conceived by companies themselves who should be interested in creating a unique code. Three main methods are found for prefixing the numeric identifier – with a space (gap),[1] with nothing (concatenated), and with a dash (or hyphen).

For example, ABT-199 is a compound developed at Abbott Laboratories, and this name has been used in early publications of research results. Later the compound was assigned the international nonproprietary name (INN) venetoclax. Similarly, other compounds may be given a USAN or BAN for example. Finally, the compound may be given a trade name for example for marketing purposes.

A long list of code designations with corresponding trade names can be found in Appendix IV of the USP Dictionary, see article on drug nomenclature.

Note that this convention of composing compound identifiers from a company identifier followed by a number is not always followed. For example, the letter code may reflect a therapeutic/disease area or an internal project name. A randomly picked example is SC for spinal cord injury.[2]

A to F

G to L

M to S

T to Z

Notes and References

  1. Web site: ArQule clinical pipeline. 2016-09-16.
  2. Web site: SC0806 clinical trial . 2018-07-26.
  3. Web site: AbbVie spun out of Abbott . 30 December 2012 . 2016-09-15.
  4. Web site: AbbVie pipeline, using ABBV- as prefix . 2016-09-16.
  5. Web site: ADL5747 . 2008-03-19.
  6. Web site: Amgen goes 6-for-6 in Phase III . 17 March 2014 . 2014-11-25.
  7. Web site: Overview of R&D Pipeline . 2018-12-30.
  8. Web site: Our Portfolio . Arecor Therapeutics . 12 June 2023.
  9. News: How Pfizer has shifted U.S. profits overseas for years. Reuters. 16 November 2015. 2019-11-06. Drawbaugh. Tom Bergin.
  10. Web site: Edison outlook report on YM Biosciences. 2016-09-19.
  11. Web site: Eagle Pharmacy – Pharmaceutical Compounding . 2016-04-26.
  12. Web site: Genentech Pipeline. 2016-09-29.
  13. GDC-0152. Journal of Medicinal Chemistry. 59. 23. 10549–10563. 10.1021/acs.jmedchem.6b01022. 27682507. 2016. Crawford. Terry D.. Romero. F. Anthony. Lai. Kwong Wah. Tsui. Vickie. Taylor. Alexander M.. De Leon Boenig. Gladys. Noland. Cameron L.. Murray. Jeremy. Ly. Justin. Choo. Edna F.. Hunsaker. Thomas L.. Chan. Emily W.. Merchant. Mark. Kharbanda. Samir. Gascoigne. Karen E.. Kaufman. Susan. Beresini. Maureen H.. Liao. Jiangpeng. Liu. Wenfeng. Chen. Kevin X.. Chen. Zhongguo. Conery. Andrew R.. Côté. Alexandre. Jayaram. Hariharan. Jiang. Ying. Kiefer. James R.. Kleinheinz. Tracy. Li. Yingjie. Maher. Jonathan. Pardo. Eneida. 29.
  14. GNE-272. Journal of Medicinal Chemistry. 59. 23. 10549–10563. 10.1021/acs.jmedchem.6b01022. 27682507. 2016. Crawford. Terry D.. Romero. F. Anthony. Lai. Kwong Wah. Tsui. Vickie. Taylor. Alexander M.. De Leon Boenig. Gladys. Noland. Cameron L.. Murray. Jeremy. Ly. Justin. Choo. Edna F.. Hunsaker. Thomas L.. Chan. Emily W.. Merchant. Mark. Kharbanda. Samir. Gascoigne. Karen E.. Kaufman. Susan. Beresini. Maureen H.. Liao. Jiangpeng. Liu. Wenfeng. Chen. Kevin X.. Chen. Zhongguo. Conery. Andrew R.. Côté. Alexandre. Jayaram. Hariharan. Jiang. Ying. Kiefer. James R.. Kleinheinz. Tracy. Li. Yingjie. Maher. Jonathan. Pardo. Eneida. 29.
  15. Web site: First patients dosed in phase II study of GS-248 in systemic sclerosis . Bioworld Science . Clarivate Analytics . 27 January 2021.
  16. Web site: MBX 2109 . 2024-02-12.
  17. Web site: Pipeline – AstraZeneca. 2018-12-30.
  18. Web site: Neurocrine Vmat2 inhibitor NBI-98854 . 2016-09-13 . dead . https://web.archive.org/web/20150130124821/http://www.neurocrine.com/pipeline/nbi-98854-vmat2-inhibitor/ . 2015-01-30 .
  19. Web site: Regeneron PCSK9 Antibody REGN727 . 2012-04-17 . dead . https://web.archive.org/web/20120416102019/http://www.regeneron.com/regn727 . 2012-04-16 .
  20. Web site: Sunesis BTK inhibitor SNS-062 . 2016-09-15.
  21. Sensei biotherapeutics anti VISTA . October 2021 . 2021-11-29.
  22. Web site: Theravance Biopharma Pipeline . Theravance pipeline background image . 2024-02-12.
  23. Web site: Pipeline . Terns Pharma pipeline . 27 January 2021.
  24. Web site: TH-302 clinical trial . 2013-07-23.
  25. Web site: MM&M News . 2009-02-16. 2008-12-18 .
  26. Web site: TransMolecular Product Pipeline . 2007-11-18 . https://web.archive.org/web/20070729050538/http://transmolecular.com/product_pipeline.html . 2007-07-29 . dead .
  27. Web site: Pipeline . Totus Medicines Pipeline . 25 August 2023.
  28. Web site: TOS-358 Clinical Trial . 25 August 2023.
  29. Web site: Preclinical characterization of TOS-358, a potent and selective covalent inhibitor of wild-type and mutant PI3Kα with superior anticancer activity . 25 August 2023.
  30. Web site: Taisho Press Release . 2008-01-07.
  31. Web site: UCL1684 at pubchem.gov . 2018-03-24.
  32. Web site: Exelixis HSP90 inhibitor XL888 . 2016-09-16 . https://web.archive.org/web/20160918144029/http://www.exelixis.com/pipeline/xl888 . 2016-09-18 . dead .